TY - JOUR T1 - Prevalence and Correlation of Metabolic Syndrome in Psoriasis Vulgaris: A Cross‐Sectional Study AU - Juwala, S. AU - Pravin, A.J.S. AU - Jaffer, Azeem AU - Simon, J. JO - Research Journal of Medical Sciences VL - 18 IS - 10 SP - 587 EP - 591 PY - 2024 DA - 2001/08/19 SN - 1815-9346 DO - makrjms.2024.10.587.591 UR - https://makhillpublications.co/view-article.php?doi=makrjms.2024.10.587.591 KW - Psoriasis vulgaris KW - metabolic syndrome KW - cardiovascular disease KW - diabetes KW - systemic inflammation KW - psoriasis area and severity index (PASI) AB -

Psoriasis vulgaris is a chronic, immune‐mediated Inflammatory skin disorder associated with systemic inflammation. Emerging evidence indicates that psoriasis is linked with metabolic syndrome (MetS), a cluster of risk factors for cardiovascular disease, diabetes and other metabolic disorders. This study explores the prevalence and correlation of MetS in psoriasis vulgaris, emphasizing the need for integrated management addressing both dermatological and systemic health. This study aims to determine the prevalence of metabolic syndrome in psoriasis vulgaris patients and investigate its correlation with disease severity, age, gender and other factors. A cross‐sectional study was conducted with 75 psoriasis patients and 100 healthy controls. Psoriasis was diagnosed clinically and/or histopathologically. Participants underwent clinical evaluation, anthropometric measurements and laboratory tests for metabolic parameters. MetS was diagnosed according to the IDF criteria. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI). The prevalence of MetS was significantly higher in psoriasis patients (40%) compared to controls (15%, p<0.001). Psoriasis patients exhibited higher rates of elevated waist circumference (67%), blood pressure (53%), fasting glucose (37%), low HDL cholesterol (56%), and elevated triglycerides (47%). No significant correlation was found between psoriasis severity (PASI score) and MetS. MetS was most prevalent in the 40‐59 age group, with a higher proportion in women. Psoriasis vulgaris is strongly associated with an increased prevalence of metabolic syndrome. These findings highlight the importance of early screening and management of metabolic diseases in psoriasis patients to reduce the risk of cardiovascular and metabolic comorbidities.

ER -